Stockholm3 is a blood test that helps to predict risk of clinically significant prostate cancer in men aged 45-74 years with a PSA level of at least 1.5 ng/ml and no previous diagnosis of prostate cancer.
It provides clear, interpretable results (High Risk with recommendation for referral to a urologist for further investigation, or Low or Normal Risk).
Stockholm3 is equivalent across diverse ethnicities, and has been prospectively validated in more than 90,000 men with results published in more than 30 peer reviewed articles. Publications include the NICE briefing (August 2022) which is helpful in suggesting that Stockholm3 is more effective at predicting risk of prostate cancer than PSA alone.
How it works?
Stockholm3 testing combines genetic markers, proteins, and clinical data in an algorithm to help identify clinically significant prostate cancer and provides an opportunity for screening in primary or secondary care settings.
Key characteristics
- Increased early detection – increased sensitivity.
- Increased specificity reduces over testing, over diagnosis, over treatment and unnecessary biopsies (by 50%).
- Higher accuracy compared to PSA and other prostate cancer risk calculations.
- PSA testing cannot distinguish between aggressive and benign tumours.
- Validated in combination with MRI and in multiple ethnicities.
- Shown to detect clinically significant prostate cancers in PSA levels of 1.5 – 2.9 ng/ml.